Cargando…

A strategy for effective latent HIV reactivation using subtherapeutic drug doses

Cell state switches underlie a plethora of biological phenomena and disease treatment strategies. Hence the ability to efficiently switch states in a chosen direction is of central importance in a number of scenarios. Increasing the concentration of an effector that results in a given switch is ofte...

Descripción completa

Detalles Bibliográficos
Autores principales: Cotterell, James, Neely, G. Gregory
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5709488/
https://www.ncbi.nlm.nih.gov/pubmed/29192171
http://dx.doi.org/10.1038/s41598-017-00097-9
_version_ 1783282789314985984
author Cotterell, James
Neely, G. Gregory
author_facet Cotterell, James
Neely, G. Gregory
author_sort Cotterell, James
collection PubMed
description Cell state switches underlie a plethora of biological phenomena and disease treatment strategies. Hence the ability to efficiently switch states in a chosen direction is of central importance in a number of scenarios. Increasing the concentration of an effector that results in a given switch is often limited by side effects. Approaches are thus increasingly sought to bypass these constraints, increasing the frequency of state switching without increasing the frequency of the side effect. Here, we employ dynamical systems theory to uncover a simple strategy as to how to maximize the probability of reactivating latent Human immunodeficiency virus (HIV) whilst maintaining minimal side effects. We demonstrate that continuous supply of an effector is significantly more likely to result in a switch with minimal side effects than the same effector supplied in temporally discrete doses. Importantly this continual dosage is likely to occur far below the Minimum effective dose at a concentration that has classically been thought subtherapeutic. We therefore suggest that in many interventional settings there exists potential to reduce drug dose much further than has previously been thought possible yet still maintaining efficacy.
format Online
Article
Text
id pubmed-5709488
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-57094882017-12-06 A strategy for effective latent HIV reactivation using subtherapeutic drug doses Cotterell, James Neely, G. Gregory Sci Rep Article Cell state switches underlie a plethora of biological phenomena and disease treatment strategies. Hence the ability to efficiently switch states in a chosen direction is of central importance in a number of scenarios. Increasing the concentration of an effector that results in a given switch is often limited by side effects. Approaches are thus increasingly sought to bypass these constraints, increasing the frequency of state switching without increasing the frequency of the side effect. Here, we employ dynamical systems theory to uncover a simple strategy as to how to maximize the probability of reactivating latent Human immunodeficiency virus (HIV) whilst maintaining minimal side effects. We demonstrate that continuous supply of an effector is significantly more likely to result in a switch with minimal side effects than the same effector supplied in temporally discrete doses. Importantly this continual dosage is likely to occur far below the Minimum effective dose at a concentration that has classically been thought subtherapeutic. We therefore suggest that in many interventional settings there exists potential to reduce drug dose much further than has previously been thought possible yet still maintaining efficacy. Nature Publishing Group UK 2017-11-30 /pmc/articles/PMC5709488/ /pubmed/29192171 http://dx.doi.org/10.1038/s41598-017-00097-9 Text en © The Author(s) 2017 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
spellingShingle Article
Cotterell, James
Neely, G. Gregory
A strategy for effective latent HIV reactivation using subtherapeutic drug doses
title A strategy for effective latent HIV reactivation using subtherapeutic drug doses
title_full A strategy for effective latent HIV reactivation using subtherapeutic drug doses
title_fullStr A strategy for effective latent HIV reactivation using subtherapeutic drug doses
title_full_unstemmed A strategy for effective latent HIV reactivation using subtherapeutic drug doses
title_short A strategy for effective latent HIV reactivation using subtherapeutic drug doses
title_sort strategy for effective latent hiv reactivation using subtherapeutic drug doses
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5709488/
https://www.ncbi.nlm.nih.gov/pubmed/29192171
http://dx.doi.org/10.1038/s41598-017-00097-9
work_keys_str_mv AT cotterelljames astrategyforeffectivelatenthivreactivationusingsubtherapeuticdrugdoses
AT neelyggregory astrategyforeffectivelatenthivreactivationusingsubtherapeuticdrugdoses
AT cotterelljames strategyforeffectivelatenthivreactivationusingsubtherapeuticdrugdoses
AT neelyggregory strategyforeffectivelatenthivreactivationusingsubtherapeuticdrugdoses